Features | Partner Sites | Information | LinkXpress
Sign In
FOCUS DIAGNOSTICS, INC.
AB Sciex
RANDOX LABORATORIES

Clostridium difficile Assay Receives FDA Clearance

By Labmedica International staff writers
Posted on 28 Nov 2013
Image: Micrograph of Clostridium difficile made from an impression smear of 72-hour growth on anaerobe blood agar (Photo courtesy of Dr. Gilda Jones).
Image: Micrograph of Clostridium difficile made from an impression smear of 72-hour growth on anaerobe blood agar (Photo courtesy of Dr. Gilda Jones).
An assay which detects nucleic acids encoding the toxin A gene and toxin B gene sequences of toxigenic strains of Clostridium difficile has received official clearance.

The assay, manufactured by IntelligentMDx (Waltham, MA, USA) can detect C. difficile in human liquid or soft stool specimens collected from patients suspected of having Clostridium difficile-associated disease.

The assay is called IMDx C. difficile and is designed for use with Abbott m2000 Real Time system (Abbott Molecular; Abbott Park, IL, USA). This is the third test from IMDx to receive US Food and Drug Administration (FDA; Silver Springs, MD, USA) clearance within three months for use on Abbott’s fully automated m2000 system and follows clearances of the IMDx VanR for Abbott m2000 and IMDx Flu A/B and RSV for Abbott m2000 assays.

Analytical reactivity studies demonstrated that the IMDx C. difficile for Abbott m2000 assay is capable of detecting the 31 different toxigenic C. difficile strains that were tested. These strains represent the global diversity of C. difficile strains, including nucleosome assembly protein I (NAP1), and toxin B (tcdB)-variant strains, such as 1470. The IMDx C. difficile for Abbott m2000 assay is part of a broad real-time polymerase chain reaction PCR test menu designed, developed, and manufactured for use on Abbott’s RealTime m2000 system under a multi-year distribution agreement with Abbott.

Effective molecular diagnostic tests for early detection of C. difficile remain critical to help control the spread of infection and the threat of more serious complications. C. difficile is the leading cause of hospital-acquired diarrhea and may cause more severe intestinal conditions such as pseudomembranous colitis. According to the US Centers of Disease Control and Prevention (CDC; Atlanta, GA, USA) C. difficile infection is linked to approximately 14,000 deaths in the USA annually.

Alice Jacobs Nesselrodt, MD, Chairman and CEO of IMDx, said, “FDA clearance of the IMDx C. difficile for Abbott m2000 assay comes at a pivotal time when incidence of C. difficile infection and severity in both hospital and community settings is increasing. Detection of a wide variety of C. difficile strains, including hypervirulent strains, by the IMDx C. difficile for Abbott m2000 assay will help ensure that a high number of cases of C. difficile are detected in a timely manner, regardless of the source of infection.”

Related Links:

IntelligentMDx
Abbott Molecular 
US Centers of Disease Control and Prevention



PURITAN MEDICAL
GREINER-BIO-ONE
ADVANCED INSTRUMENTS
BioConferenceLive

Channels

Clinical Chemistry

view channel
Image: The ICON 25 hCG point-of-care pregnancy test (Photo courtesy of Beckman Coulter).

Pregnancy Tests Evaluated During Early Gravidity

The predominant hormone human chorionic gonadotropin (hCG) variant in urine, hCG β core fragment (hCGβcf), has been demonstrated to cause false-negative results in qualitative point-of-care (POC) hCG devices.... Read more

Genetic Tests

view channel
Image: The Quant-iT PicoGreen dsDNA Assay Kit (Photo courtesy of Invitrogen).

Blood Test Provides Rapid Method of Detecting Solid Cancers

Circulating tumor DNA (ctDNA) is a promising biomarker for noninvasive assessment of cancer burden, but existing detection methods have insufficient sensitivity or patient coverage for broad clinical applicability.... Read more

Hematology

view channel

Blood Donations Screened for Viruses Using Multiplex Assay

A global healthcare company was chosen to partner the Japanese Red Cross (JRC; Tokyo, Japan) for nucleic acid screening of the nation's blood supply. Under the terms of the 7-year agreement, the healthcare company, Grifols (Barcelona, Spain) will provide the JRC with its newest automation platform, the Procleix Panther... Read more

Pathology

view channel
Image: Immunostaining of human lung tissue, fixed with HOPE, from a patients suffering from legionnaire\'s disease. One legionella protein (red-brown), the bacteria-containing vacuoles and individual legionella inside the scavenger cells can be detected. The infection process can be observed immediately using proteomics (Photo courtesy of Braunschweig University of Technology).

Novel Method Prepares Tissue Samples for Analyzing Proteins

A new way of preparing patient tissue for analyses might soon become the new standard, possibly replacing tissues fixed with formalin, before they are embedded in wax-like paraffin and cut into razor-thin slices.... Read more

Industry News

view channel

Roche and Hitachi Renew Alliance in Diagnostics

Roche (Basel, Switzerland) and Hitachi (Tokyo, Japan) have renewed their alliance in the diagnostics business by 10-years for the joint development and manufacture of the next generation of instruments and workflow automation solutions for medical laboratories. The renewed alliance marks a significant milestone towards... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.